Mark Neumann

Insider Reports History

Identity 1 identity field
Location
Bedminster, NJ
SEC filing record 1 source field
Reporting-owner signature
/s/ Michael Greco, Attorney-in-Fact
SEC evidence 1 source field
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Mark Neumann

Form 4 holding EVP, Chief Commercial Officer

Intra-Cellular Therapies, Inc.

Security class
Performance Stock Units
Shares / value
0
Estimated value
$0
Report date
02 Apr 2025
Price
$132.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP, Chief Commercial Officer

Intra-Cellular Therapies, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
02 Apr 2025
Price
$132.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Commercial Officer, Strategy Officer

Veradermics, Inc

Security class
Stock Option (Right to Buy)
Shares / value
102,885
Estimated value
Report date
03 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding EVP, Chief Commercial Officer

Intra-Cellular Therapies, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
02 Apr 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Mark Neumann

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .